Sector News

Novo Nordisk A/S: Changes in Novo Nordisk’s Executive Management

November 25, 2014
Life sciences
(GLOBE NEWSWIRE) – Following a change in the distribution of responsibilities among the members of its Executive Management, Novo Nordisk has reduced the number of executives from seven to six. In this connection Executive Vice President and Chief of Staffs Lise Kingo has decided to leave Novo Nordisk.
 
Her areas of responsibility will be taken over by other members of Executive Management. As from today:
 
– Corporate People & Organisation and Business Assurance report to Lars Fruergaard Jørgensen
– Corporate Stakeholder Engagement reports to Jakob Riis
– Corporate Communications reports to Lars Rebien Sørensen.
 
Commenting on the changes, Lars Rebien Sørensen, CEO, says: “I would like to thank Lise for her many contributions to Novo Nordisk during her impressive career in the company. Of special note is her leadership in driving the company’s strategy within sustainable development, corporate branding and public affairs, which has earned Novo Nordisk recognition as a respected global business. I wish her the best of luck in the future.”
 
Lise Kingo says: “I have really enjoyed being part of Novo Nordisk throughout my career, not least during my time as a member of its Executive Management. It has been a fantastic journey and I wish the company and my colleagues all the best in their onward journey. This is the beginning of a new chapter in which I plan to utilise my experience and insights in boards of companies and organisations internationally.”
 
Following the above-mentioned changes, Novo Nordisk’s Executive Management is now composed as follows:
 
Lars Rebien Sørensen, CEO (chief executive officer).
 
Kåre Schultz, president and COO (chief operating officer), responsible for Sales and Product Supply.
 
Jesper Brandgaard, executive vice president and CFO (chief financial officer), responsible for Finance, Legal, and Investor Relations.
 
Lars Fruergaard Jørgensen, executive vice president, responsible for Corporate IT, Corporate Quality, Corporate Development, Corporate People & Organisation and Business Assurance.
 
Jakob Riis, executive vice president, responsible for Marketing, Medical Affairs and Corporate Stakeholder Engagement. 
 
Mads Krogsgaard Thomsen, executive vice president and chief science officer, responsible for Research, Development and Regulatory Affairs.
 
Source: Novo Nordisk
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”